JP3605528B2 - Weight gain inhibitor - Google Patents
Weight gain inhibitor Download PDFInfo
- Publication number
- JP3605528B2 JP3605528B2 JP17572099A JP17572099A JP3605528B2 JP 3605528 B2 JP3605528 B2 JP 3605528B2 JP 17572099 A JP17572099 A JP 17572099A JP 17572099 A JP17572099 A JP 17572099A JP 3605528 B2 JP3605528 B2 JP 3605528B2
- Authority
- JP
- Japan
- Prior art keywords
- royal jelly
- degradation product
- weight gain
- raw
- protease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000004584 weight gain Effects 0.000 title claims description 18
- 235000019786 weight gain Nutrition 0.000 title claims description 18
- 239000003112 inhibitor Substances 0.000 title claims description 10
- 229940109850 royal jelly Drugs 0.000 claims description 74
- 239000007857 degradation product Substances 0.000 claims description 32
- 108091005804 Peptidases Proteins 0.000 claims description 15
- 239000004365 Protease Substances 0.000 claims description 15
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 230000009471 action Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- 235000019750 Crude protein Nutrition 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 238000000354 decomposition reaction Methods 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 108090000284 Pepsin A Proteins 0.000 description 4
- 102000057297 Pepsin A Human genes 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 235000012631 food intake Nutrition 0.000 description 4
- 229940111202 pepsin Drugs 0.000 description 4
- 230000017854 proteolysis Effects 0.000 description 4
- 108010019160 Pancreatin Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 102000038379 digestive enzymes Human genes 0.000 description 3
- 108091007734 digestive enzymes Proteins 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229940055695 pancreatin Drugs 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- WXBXVVIUZANZAU-UHFFFAOYSA-N 2E-decenoic acid Natural products CCCCCCCC=CC(O)=O WXBXVVIUZANZAU-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 230000007515 enzymatic degradation Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- WXBXVVIUZANZAU-CMDGGOBGSA-N trans-2-decenoic acid Chemical compound CCCCCCC\C=C\C(O)=O WXBXVVIUZANZAU-CMDGGOBGSA-N 0.000 description 2
- QHBZHVUGQROELI-SOFGYWHQSA-N (E)-10-hydroxydec-2-enoic acid Chemical compound OCCCCCCC\C=C\C(O)=O QHBZHVUGQROELI-SOFGYWHQSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108091005658 Basic proteases Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 240000001972 Gardenia jasminoides Species 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 241000208251 Gymnema Species 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101001026869 Mus musculus F-box/LRR-repeat protein 3 Proteins 0.000 description 1
- 108091005507 Neutral proteases Proteins 0.000 description 1
- 102000035092 Neutral proteases Human genes 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000567 anti-anemic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000003471 anti-radiation Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Jellies, Jams, And Syrups (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
【0001】
【発明の属する技術分野】
本発明は、ローヤルゼリー及び/又はローヤルゼリーのプロテアーゼによる分解物を有効成分とする体重増加抑制剤に関する。
【0002】
【従来の技術】
近年、飽食の時代といわれ、食生活が豊かになり、また、日常の運動不足から肥満に悩む人が増加している。それに伴って、高血圧、糖尿病などのいわゆる成人病が大きな問題となっている。そのため、健康上あるいは美容上の理由から、痩せるためにダイエット組成物を摂取する人が増加している。
【0003】
例えば、ダイエット効果(肥満抑制効果)を有するものとして、ギムネマエキス、クチナシエキス、小麦ふすま、とうもろこし外皮などの水不溶性食物繊維や、グアーガム、難消化性デキストリンなどの水溶性食物繊維などが知られている。これらの成分は、栄養素が生体内に吸収されるのを阻害する作用を有するため、優れたダイエット効果を示す。
【0004】
ところで、ローヤルゼリーは、ミツバチの分泌腺(下咽頭腺、大腮腺)から分泌される乳白色を帯びた強い酸味のある物質で、女王蜂を育てるための特別な餌となる物質である。ローヤルゼリーの成分についてはまだ不明の点もあるが、ビタミン、ミネラル、アミノ酸、アセチルコリン、10−ヒドロキシデセン酸、ステロール、ホルモンなどの豊富な栄養分を含有し、更年期障害予防作用、抗貧血作用、老化防止、抗放射線作用、抗ガン作用、血流増加作用、抗動脈硬化作用(コレステロール低下作用、血圧正常化作用)、リウマチ・神経痛予防作用、健康増進作用などの人体に対して好ましい生理活性を持つことが知られている。そのため、古くから、生タイプ、カプセルタイプ、飲料タイプなどの健康食品、医薬品、化粧品などに利用されている。
【0005】
採取された原液、いわゆる生ローヤルゼリーは、独特のえぐ味及び臭気を有しており、食べる際に抵抗感を覚える人が多く、最近はアルコール抽出ローヤルゼリーやプロテアーゼ処理ローヤルゼリー等が開発され、これらを添加した飲料として摂取される場合が多くなってきた。例えば、本出願人による特許第2623044号(特開平5−123119号)には、基質に対する作用部位の異なる二種類以上のプロテアーゼで生ローヤルゼリーを処理することにより、生ローヤルゼリーと同様な成分を含有し、しかも透明で安定性に優れ、飲料などにも添加しやすく、したがって経口摂取しやすい透明なローヤルゼリー分解物が得られることが開示されている。
【0006】
酵素消化したローヤルゼリーの生理活性については、本出願人によるローヤルゼリーのプロテアーゼによる分解物で分子量3,000以下のペプチドを有効成分として含有する経口摂取用育毛剤(特開平8−104645号)、同様に分子量3,000以下のペプチドを有効成分として含有する感染防御機能増強剤(特開平8−59499号)が開示されている。
【0007】
【発明が解決しようとする課題】
しかしながら、上述したようなダイエット効果を有する成分を摂取しすぎると、軟便や下痢症状、腸粘膜の炎症、免疫力の低下を引き起こしたり、精神的に不安定な状態になってしまうことがあり、また、味や食感の問題から十分な量(有効量)を食品などに添加することが困難であった。
【0008】
したがって、本発明の目的は、体重増加抑制効果と共に、他の様々な生理活性機能をも期待でき、安全で、経口摂取しやすく、手軽に摂取することのできる体重増加抑制剤を提供することにある。
【0009】
【課題を解決するための手段】
本発明者らは、ローヤルゼリーの酵素分解物の生理活性機能を研究する過程で、ローヤルゼリー及びローヤルゼリの酵素分解物が、意外にも体重増加抑制効果を有することを見出し、この事実に基づき本発明を完成するに至った。
【0010】
すなわち、本発明は、ローヤルゼリー及び/又はローヤルゼリーのプロテアーゼによる分解物を有効成分とすることを特徴とする体重増加抑制剤である。
【0011】
本発明によれば、ローヤルゼリー及び/又はローヤルゼリーのプロテアーゼによる分解物により、後述する実施例に示されるように体重増加抑制効果がもたらされ、下痢症状などを引き起こす虞れもなくダイエット効果が期待できる。特に、ローヤルゼリー分解物は、エグ味や臭気がなく、水に溶けやすく、熱やpHによるタンパク質の凝固・沈殿がないため、安全で、経口摂取しやすく、手軽に摂取することができる。
【0012】
そして、ローヤルゼリーの有する様々な生理活性機能、及びローヤルゼリーのプロテアーゼによる分解物の有する育毛効果、感染防御機能増強効果、さらにはカルシウム吸収促進効果(特願平10−90808号)などの生理活性機能も期待できる。
【0013】
本発明において、前記分解物は、分子量3,000以下のペプチドを主成分とするものであることが好ましい。
【0014】
【発明の実施の形態】
本発明の体重増加抑制剤の有効成分は、ローヤルゼリー及び/又はローヤルゼリーのプロテアーゼによる分解物である。
【0015】
本発明において、ローヤルゼリーとしては、生ローヤルゼリーが用いられる。また、本発明において、ローヤルゼリーのプロテアーゼによる分解物(以下、ローヤルゼリー分解物と略称する)は、ローヤルゼリーの懸濁液に、プロテアーゼ、好ましくは基質に対する作用部位の異なる二種類以上のプロテアーゼを、同時又は逐次添加して室温以上の温度に保持して酵素反応させることにより得ることができる。
【0016】
上記プロテアーゼとしては、微生物や植物起源の酸性プロテアーゼ、中性プロテアーゼ、アルカリプロテアーゼや、ペプシン、パンクレアチンなどの哺乳動物由来の消化酵素など、通常、食品加工に用いられているものを使用することができ、これらの中から基質に対する作用部位の異なる二種類以上を選択して用いることが好ましい。
【0017】
プロテアーゼによる処理は、タンパク質の分解率を経時的に測定しながら行い、最終分解率は使用するプロテアーゼにより異なるが、分解率が好ましくは75%以上、より好ましくは85%以上となるまで行うのがよい。なお、上記製造法の詳細は、前記特許第2623044号に記載されている。
【0018】
こうして得られたローヤルゼリー分解物は、分子量3,000以下のペプチドを含有しており、タンパク質が分解されてペプチド化している以外は、生ローヤルゼリーと同様な成分を含有している(固形分中、タンパク質:36〜42%、糖質:45〜52%、脂質:13〜15%、デセン酸:5〜6%)。
【0019】
そして、このローヤルゼリー分解物は、そのまま食しても喉を刺すような刺激もなく、むしろ若干の旨味と甘さがあるものである。また、水溶液にしたときに透明で安定性に優れており、飲料などにも添加しやすく、経口摂取しやすいものである。
【0020】
上記ローヤルゼリー分解物は、そのまま溶液状で用いてもよく、凍結乾燥などの手段により粉末化してもよい。また、このようなローヤルゼリー分解物としては、例えば、「バイオサンローヤル」(商品名、株式会社バイオックス製)などの市販品を用いることもできる。
【0021】
本発明の体重増加抑制剤は、上記ローヤルゼリー及び/又はローヤルゼリー分解物を、例えば、カプセル剤などにしてもよく、適当な賦形剤を添加して錠剤などにしてもよい。また、ハチミツ、栄養ドリンク、清涼飲料などに添加・溶解させて、飲料などの流動状のものにすることもできる。飲料などに添加する場合、上記ローヤルゼリー及び/又はローヤルゼリー分解物を乾燥物換算で0.5〜5重量%、好ましくは1〜3重量%添加する。
【0022】
本発明の体重増加抑制剤の有効成分であるローヤルゼリー及び/又はローヤルゼリー分解物の好ましい摂取量は、乾燥物換算で1日当たり0.5〜10gである。
【0023】
【実施例】
以下、実施例を挙げて本発明を具体的に説明する。
製造例
生ローヤルゼリー100gに温水を加えて、ローヤルゼリーの懸濁液1kgを調製し、20%水酸化ナトリウム溶液を用いてpH4に調整した。この懸濁液に、哺乳動物の消化酵素であるペプシン(1:10,000、シグマ社製)0.1gを添加し、45℃、6時間酵素処理を行い、ペプシン処理液を得た。次に、このペプシン処理液を、20%水酸化ナトリウム溶液を用いてpH8に調整した後、哺乳類の消化酵素であるパンクレアチン(2,000,000単位/g、シグマ社製)0.1gを添加し、45℃、6時間酵素処理を行った。
【0024】
この酵素処理液を、80℃で10分間加熱して酵素を失活させた後、濾過して異物や不溶性残渣を除去して透明な溶液を得た。この溶液をはじめに用いた生ローヤルゼリーと同じ重さである100gまで減圧濃縮して、透明な溶液状のローヤルゼリー分解物を得た。なお、このローヤルゼリー分解物は、「バイオサンローヤル」(商品名、株式会社バイオックス製)として市販されているものと同様のものである。
【0025】
上記酵素処理時間は、酵素反応開始後0、2、4、6時間後にそれぞれタンパク質の分解率を以下に示す方法で測定し、分解率が最高に達した時点とした。
【0026】
・タンパク質分解率の測定方法
サンプル2.0mlに、等量の10%トリクロル酢酸(TCA)を加えて遠心を行い、この上清を希釈した後、ローリー法で比色定量し、TCA可溶性成分の量の推移を調べた。なお、ローヤルゼリー中の粗タンパク質は、TCA溶液のかわりに等量の水を加えた溶液を用いて、同様に比色定量して求めた。そして、下記数1に示す式により、タンパク質の分解率を求めた。
【0027】
【数1】
分解率(%)={(c−b)/(a−b)}×100
a:ローヤルゼリー分解物の粗タンパク質含有量
b:ローヤルゼリー分解物のTCA可溶性成分の含有量
c:酵素処理サンプルのTCA可溶性成分の含有量
【0028】
上記方法により求めた6時間酵素(パンクレアチン)処理後のタンパク質の分解率は、91.6%であった。
【0029】
また、得られたローヤルゼリー分解物と、生ローヤルゼリーとに含まれる粗タンパク質について分子量分布をHPLCで測定し、比較した。その結果を図1に示す。図1中、Aは上記製造例で得られたローヤルゼリー分解物、Bは生ローヤルゼリーの結果を示す。
【0030】
図1の結果から、上記製造例で得られた透明なローヤルゼリー分解物中の粗タンパク質の分子量分布を、生ローヤルゼリー中の粗タンパク質の分子量分布と比較すると、製造例で得られたローヤルゼリー分解物中には、分子量10,000以上のものがほとんどなくなって、分子量500〜3,000のペプチドが主成分となっている。このことは、電気泳動等の結果からも確認した。
【0031】
すなわち、上記製造例で得られたローヤルゼリー分解物は、タンパク質が分解されてペプチド化している以外は、生ローヤルゼリーと同様な成分を含有し、ペプチドとしては、特に生理機能を有すると言われている分子量数百〜数千のペプチドを多く含有していることが分かる。
【0032】
なお、上記製造例で得られたローヤルゼリー分解物は、エグ味や臭気がなく、弱酸性の飲料に添加しても生ローヤルゼリーのように凝集・沈殿することなく容易に溶解した。
【0033】
実施例
10週齢のKKAy系雄マウス(自然発症糖尿病モデルマウス)を用いて、生理食塩水投与群(以下、コントロール群という)、生ローヤルゼリー投与群(以下、生RJ群という)、ローヤルゼリー分解物投与群(以下、PRJ群という)に分け(各群6匹)、12時間毎の明暗サイクルの環境下で、固形飼料CA−1(商品名、日本クレア(株)社製)及び水は自由摂取として4週間飼育した。
【0034】
コントロール群においては、1回当たりの生理食塩水の投与量を500mg/匹とし、生RJ群及びPRJ群においては、1回当たりの生ローヤルゼリー及びローヤルゼリー分解物の投与量を、それぞれのデセン酸量が同じになるように決定し、生ローヤルゼリーは300mg/体重kg(乾燥物換算105mg/体重kg)、ローヤルゼリー分解物(BX−7 L−50、商品名、株式会社バイオックス製)は730mg/体重kg(乾燥物換算121mg/体重kg)とした。各被験物質は必要量を小分けにして冷凍保存し、冷蔵下にて融解させた後、胃ゾンデを用いて28日間連続投与した。なお、摂餌・摂水量は7日毎に測定し、各被験物質の投与前に体重測定を行い、体重増加を見た。摂餌・摂水量の結果を図2に、体重増加の結果を図3に示す。
【0035】
図2から分かるように、各群において摂餌・摂水量に有意差は見られなかった。一方、図3から、生RJ群及びPRJ群の体重増加は、コントロール群に対して有意に抑制されることが分かった(p<0.05)。
【0036】
【発明の効果】
以上説明したように、本発明の体重増加抑制剤は、ローヤルゼリー及び/又はローヤルゼリー分解物を含有することにより、体重増加抑制効果をもたらすことができ、下痢症状などを引き起こす虞れもなくダイエット効果が期待できる。特に、ローヤルゼリー分解物は、エグ味や臭気がなく、水に溶けやすく、熱やpHによるタンパク質の凝固・沈殿がないため、安全で、経口摂取しやすく、手軽に摂取することができる。
【0037】
さらに、ローヤルゼリー及び/又はローヤルゼリー分解物の有する様々な各種生理活性機能も期待できる。
【図面の簡単な説明】
【図1】製造例で得られたローヤルゼリー分解物中の粗タンパク質と、生ローヤルゼリー中の粗タンパク質の分子量分布を示す図である。
【図2】実験期間中の各群の摂餌・摂水量を表す図である。
【図3】実験期間中の各群の体重増加量を表す図である。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a weight gain inhibitor comprising as an active ingredient royal jelly and / or a degradation product of royal jelly by protease.
[0002]
[Prior art]
In recent years, it is said to be the time of satiety, and the eating habits have been enriched, and the number of people who suffer from obesity due to lack of daily exercise is increasing. Along with this, so-called adult diseases such as hypertension and diabetes have become a major problem. Therefore, for health or beauty reasons, an increasing number of people take a diet composition to lose weight.
[0003]
For example, water-insoluble dietary fibers such as gymnema extract, gardenia extract, wheat bran, corn hulls, and water-soluble dietary fibers such as guar gum and indigestible dextrin are known as having a diet effect (anti-obesity effect). Yes. Since these components have an action of inhibiting the absorption of nutrients into the living body, they exhibit an excellent diet effect.
[0004]
By the way, royal jelly is a milky white and sour acid substance secreted from the secretory glands of the bees (hypopharyngeal gland, large vagina gland), and is a substance serving as a special bait for growing the queen bee. The ingredients of royal jelly are still unclear, but contain abundant nutrients such as vitamins, minerals, amino acids, acetylcholine, 10-hydroxydecenoic acid, sterols, hormones, and prevent menopause, anti-anemic, and anti-aging , Anti-radiation action, anti-cancer action, blood flow increase action, anti-arteriosclerosis action (cholesterol lowering action, blood pressure normalizing action), rheumatism / neuralgia prevention action, health promotion action, etc. It has been known. For this reason, it has long been used for health foods such as raw types, capsule types, and beverage types, pharmaceuticals, and cosmetics.
[0005]
Collected stock solution, so-called raw royal jelly, has a unique taste and odor and many people feel resistance when eating. Recently, alcohol extracted royal jelly, protease treated royal jelly, etc. have been developed and added In many cases, it is consumed as a drink. For example, Japanese Patent No. 2623044 (Japanese Patent Laid-Open No. 5-123119) by the present applicant contains components similar to raw royal jelly by treating raw royal jelly with two or more types of proteases having different sites of action on the substrate. Moreover, it is disclosed that a transparent royal jelly degradation product that is transparent and excellent in stability, can be easily added to beverages and the like, and is thus easily taken orally.
[0006]
Regarding the physiological activity of enzymatically digested royal jelly, a hair-recovery agent for oral consumption containing a peptide having a molecular weight of 3,000 or less as an active ingredient by the degradation product of royal jelly by the applicant of the present invention (Japanese Patent Laid-Open No. 8-104645), An infection defense function enhancer (JP-A-8-59499) containing a peptide having a molecular weight of 3,000 or less as an active ingredient is disclosed.
[0007]
[Problems to be solved by the invention]
However, taking too much a component having a diet effect as described above may cause loose stool or diarrhea, inflammation of the intestinal mucosa, a decrease in immunity, or mental instability, In addition, it has been difficult to add a sufficient amount (effective amount) to foods and the like due to problems of taste and texture.
[0008]
Therefore, an object of the present invention is to provide a weight gain inhibitor that can be expected to have various other physiologically active functions as well as a weight gain inhibitory effect, is safe, easy to take orally, and can be taken easily. is there.
[0009]
[Means for Solving the Problems]
In the course of studying the bioactive function of the enzymatic degradation product of royal jelly, the present inventors have found that royal jelly and the enzymatic degradation product of royal jelly surprisingly have an effect of suppressing weight gain. It came to be completed.
[0010]
That is, the present invention is a weight gain inhibitor characterized by comprising royal jelly and / or a degradation product of royal jelly with a protease as an active ingredient.
[0011]
According to the present invention, royal jelly and / or a degradation product of royal jelly with a protease provides an effect of suppressing weight gain as shown in Examples described later, and a diet effect can be expected without causing diarrhea symptoms. . In particular, the royal jelly degradation product has no taste and odor, is easily dissolved in water, and does not coagulate or precipitate protein due to heat or pH, so it is safe, easy to ingest, and can be easily ingested.
[0012]
Furthermore, various physiologically active functions possessed by royal jelly, and physiologically active functions such as a hair-growth effect, a defense function enhancing effect, and a calcium absorption promotion effect (Japanese Patent Application No. 10-90808) possessed by the degradation product of royal jelly protease. I can expect.
[0013]
In the present invention, it is preferable that the degradation product contains a peptide having a molecular weight of 3,000 or less as a main component.
[0014]
DETAILED DESCRIPTION OF THE INVENTION
The active ingredient of the weight gain inhibitor of the present invention is royal jelly and / or a degradation product of royal jelly by protease.
[0015]
In the present invention, raw royal jelly is used as the royal jelly. Further, in the present invention, a degradation product of a royal jelly protease (hereinafter abbreviated as a royal jelly degradation product) is combined with a protease, preferably two or more types of proteases having different action sites for a substrate, in a royal jelly suspension. It can be obtained by sequentially adding and maintaining the temperature at room temperature or higher to cause an enzyme reaction.
[0016]
As the protease, those commonly used in food processing, such as acidic proteases derived from microorganisms and plants, neutral proteases, alkaline proteases, and digestive enzymes derived from mammals such as pepsin and pancreatin may be used. Among these, it is preferable to select and use two or more types having different action sites for the substrate.
[0017]
The treatment with protease is performed while measuring the degradation rate of protein over time, and the final degradation rate varies depending on the protease used, but it is preferably performed until the degradation rate is 75% or more, more preferably 85% or more. Good. The details of the production method are described in the above-mentioned Japanese Patent No. 2623044.
[0018]
The thus obtained royal jelly degradation product contains a peptide having a molecular weight of 3,000 or less, and contains the same components as raw royal jelly except that the protein is decomposed and converted into a peptide (in the solid content, Protein: 36-42%, carbohydrate: 45-52%, lipid: 13-15%, decenoic acid: 5-6%).
[0019]
And this royal jelly decomposition product does not have the irritation | stimulation which stabs a throat even if it eats as it is, but rather it has some taste and sweetness. In addition, it is transparent and excellent in stability when it is made into an aqueous solution, and it can be easily added to beverages and is easily taken orally.
[0020]
The royal jelly decomposition product may be used in the form of a solution as it is, or may be pulverized by means such as freeze-drying. In addition, as such a royal jelly decomposition product, for example, a commercially available product such as “Bio-san royal” (trade name, manufactured by Biox Co., Ltd.) can be used.
[0021]
In the weight gain inhibitor of the present invention, the royal jelly and / or royal jelly degradation product may be, for example, a capsule or the like, or may be a tablet by adding an appropriate excipient. Also, it can be added to and dissolved in honey, nutrition drinks, soft drinks, etc. to make fluids such as beverages. When added to beverages, etc., the above royal jelly and / or royal jelly degradation product is added in an amount of 0.5 to 5% by weight, preferably 1 to 3% by weight in terms of dry matter.
[0022]
The preferred intake of royal jelly and / or royal jelly degradation product, which is an active ingredient of the weight gain inhibitor of the present invention, is 0.5 to 10 g per day in terms of dry matter.
[0023]
【Example】
Hereinafter, the present invention will be specifically described with reference to examples.
Manufacturing Example Warm water was added to 100 g of raw royal jelly to prepare 1 kg of a royal jelly suspension, and the pH was adjusted to 4 using a 20% sodium hydroxide solution. To this suspension, 0.1 g of mammalian digestive enzyme pepsin (1: 10,000, manufactured by Sigma) was added and subjected to enzyme treatment at 45 ° C. for 6 hours to obtain a pepsin-treated solution. Next, after adjusting this pepsin-treated solution to
[0024]
This enzyme-treated solution was heated at 80 ° C. for 10 minutes to deactivate the enzyme, and then filtered to remove foreign substances and insoluble residues to obtain a transparent solution. This solution was concentrated under reduced pressure to 100 g, which was the same weight as the raw royal jelly used first, to obtain a transparent solution-like royal jelly decomposition product. In addition, this royal jelly decomposition product is the same as that marketed as “Bio-san royal” (trade name, manufactured by Biox Co., Ltd.).
[0025]
The enzyme treatment time was measured at 0, 2, 4, and 6 hours after the start of the enzyme reaction, and the protein degradation rate was measured by the following method, and the time when the degradation rate reached the maximum.
[0026]
・ Measurement method of proteolysis rate To 2.0 ml of sample, add an equal amount of 10% trichloroacetic acid (TCA), perform centrifugation, dilute the supernatant, colorimetrically determine by the Raleigh method, The change in quantity was examined. The crude protein in royal jelly was obtained by colorimetric determination in the same manner using a solution to which an equal amount of water was added instead of the TCA solution. And the protein degradation rate was calculated | required by the formula shown to following Numerical formula 1.
[0027]
[Expression 1]
Decomposition rate (%) = {(c−b) / (a−b)} × 100
a: Crude protein content of royal jelly degradation product b: Content of TCA soluble component of royal jelly degradation product c: Content of TCA soluble component of enzyme-treated sample
The protein degradation rate after 6 hours enzyme (pancreatin) treatment determined by the above method was 91.6%.
[0029]
Moreover, molecular weight distribution was measured and compared with the crude protein contained in the obtained royal jelly degradation product and raw royal jelly. The result is shown in FIG. In FIG. 1, A is the royal jelly decomposition product obtained in the above production example, and B is the result of raw royal jelly.
[0030]
From the result of FIG. 1, when the molecular weight distribution of the crude protein in the transparent royal jelly degradation product obtained in the above production example is compared with the molecular weight distribution of the crude protein in the raw royal jelly, in the royal jelly degradation product obtained in the production example Most of them have a molecular weight of 10,000 or more, and a peptide having a molecular weight of 500 to 3,000 is the main component. This was also confirmed from the results of electrophoresis and the like.
[0031]
That is, the royal jelly degradation product obtained in the above production example contains the same components as raw royal jelly except that the protein is decomposed and converted into a peptide, and the peptide is said to have a physiological function in particular. It turns out that many peptides with a molecular weight of hundreds to thousands are contained.
[0032]
In addition, the royal jelly degradation product obtained in the above production example has no taste and odor, and even when added to a weakly acidic beverage, it was easily dissolved without aggregation and precipitation like raw royal jelly.
[0033]
Example 10 Using a KKA y strain male mouse (spontaneous diabetes model mouse) aged 10 weeks, a physiological saline administration group (hereinafter referred to as a control group), a raw royal jelly administration group (hereinafter referred to as a raw RJ group), and a royal jelly degradation It is divided into food administration groups (hereinafter referred to as PRJ group) (6 animals in each group), and under the environment of light / dark cycle every 12 hours, solid feed CA-1 (trade name, manufactured by Clea Japan Co., Ltd.) and water are They were raised for 4 weeks as free intake.
[0034]
In the control group, the dose of physiological saline per administration is 500 mg / animal, and in the raw RJ group and PRJ group, the doses of raw royal jelly and royal jelly degradation product are determined for each decenoic acid amount. The raw royal jelly is 300 mg / kg body weight (105 mg / kg body weight in terms of dry matter), and the royal jelly degradation product (BX-7 L-50, trade name, manufactured by Biox) is 730 mg / kg body weight. (121 mg / kg body weight in terms of dry matter). Each test substance was stored frozen by subdividing the required amount, and thawed under refrigeration, and then administered continuously for 28 days using a gastric sonde. In addition, food intake and water intake were measured every 7 days, body weight was measured before administration of each test substance, and weight gain was observed. The results of food intake and water intake are shown in FIG. 2, and the results of weight gain are shown in FIG.
[0035]
As can be seen from FIG. 2, there was no significant difference in food intake / water intake in each group. On the other hand, from FIG. 3, it was found that the weight gain of the raw RJ group and the PRJ group was significantly suppressed compared to the control group (p <0.05).
[0036]
【The invention's effect】
As described above, the weight gain inhibitor of the present invention contains a royal jelly and / or a royal jelly degradation product, so that it can bring about a weight gain inhibitory effect and has a diet effect without causing diarrhea symptoms. I can expect. In particular, the royal jelly degradation product has no taste and odor, is easily dissolved in water, and does not coagulate or precipitate protein due to heat or pH, so it is safe, easy to ingest, and can be easily ingested.
[0037]
Further, various physiologically active functions possessed by the royal jelly and / or the royal jelly degradation product can be expected.
[Brief description of the drawings]
BRIEF DESCRIPTION OF DRAWINGS FIG. 1 is a diagram showing the molecular weight distribution of a crude protein in a royal jelly degradation product obtained in a production example and a crude protein in raw royal jelly.
FIG. 2 is a diagram showing food intake and water intake of each group during the experiment period.
FIG. 3 is a diagram showing the weight gain of each group during the experimental period.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP17572099A JP3605528B2 (en) | 1999-06-22 | 1999-06-22 | Weight gain inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP17572099A JP3605528B2 (en) | 1999-06-22 | 1999-06-22 | Weight gain inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001002576A JP2001002576A (en) | 2001-01-09 |
| JP3605528B2 true JP3605528B2 (en) | 2004-12-22 |
Family
ID=16001069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP17572099A Expired - Fee Related JP3605528B2 (en) | 1999-06-22 | 1999-06-22 | Weight gain inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3605528B2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004075660A1 (en) * | 2003-02-27 | 2004-09-10 | Kikuji Yamaguchi | Food and drug containing royal jelly |
| CN117778511A (en) * | 2024-02-23 | 2024-03-29 | 中国农业科学院蜜蜂研究所 | Preparation method and application of royal jelly protein hypoglycemic peptide powder |
-
1999
- 1999-06-22 JP JP17572099A patent/JP3605528B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2001002576A (en) | 2001-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH09291039A (en) | Antiobesity agent containing procyanidins as active ingredients | |
| JP3782122B2 (en) | Metabolism promoter for oral intake and food containing the same | |
| JP4505707B2 (en) | Pharmaceutical composition for the treatment of stiff shoulders or coldness due to vasodilation | |
| JP3691685B2 (en) | Blood sugar level rise inhibitor | |
| CN103190483A (en) | Children growth promotion milk tea | |
| KR102000170B1 (en) | Food compositions for reducing body fat and improving intestinal function | |
| CN104839695A (en) | Non-complete nutritional formula food for inflammatory bowel disease | |
| JP3605528B2 (en) | Weight gain inhibitor | |
| JP3979543B2 (en) | Antiallergic agent and method for producing the same | |
| CN101028098B (en) | Food composition containing bone collagen peptide | |
| JP2002275087A (en) | Antidiabetic medicine and food for preventing diabetes | |
| JP5677937B2 (en) | Composition for regulating autonomic nerve activity and method for regulating autonomic nerve | |
| JP2001002577A (en) | Lipid metabolism improver | |
| KR100899556B1 (en) | Functional foods added with Maban extract | |
| KR100734944B1 (en) | Functional health food composition based on calcium lactate and rice bran | |
| KR20180056199A (en) | Manufacturing method of gum for diet containing Moringa Oleifera extract | |
| JP3641284B2 (en) | Glucose tolerance disorder improving agent | |
| KR0137897B1 (en) | Health food containing leaf of eucommia ulmoides oliver | |
| KR100834487B1 (en) | Beverages and medicines based on bamboo extract | |
| JP2978581B2 (en) | Cholesterol suppressant | |
| US20080103089A1 (en) | Compounds, Compositions, Formulations and Process for Preparation Thereof and Method of Treatment and Management of Acidity and Related Disorders | |
| CN110089751A (en) | Intestines arrange health care product | |
| JP2026049151A (en) | Diarrhea-suppressing material for dogs | |
| JP2006348049A (en) | Medicine for promoting blood flow by vasodilation and health food composition | |
| Foster et al. | Gastro-Intestinal Studies. VII. The Utilization of Ingested Protein as Influenced by Undermastication (bolting) and Overmastication (fletcherizing). |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040907 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20041004 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071008 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101008 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101008 Year of fee payment: 6 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101008 Year of fee payment: 6 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111008 Year of fee payment: 7 |
|
| LAPS | Cancellation because of no payment of annual fees |